Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2020

01-01-2020 | Obesity | Epidemiology

Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study

Authors: Seok Hun Jeong, Yoonsuk An, Choonghyun Ahn, Boyoung Park, Min Hyuk Lee, Dong-Young Noh, Sue K. Park

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Abstract

Background

Our main objective of this research was to analyze the effect of BMI on breast cancer risk according to various subtypes of breast cancer stratified with menopausal status.

Methods

By using a case–control study setting, we recruited a total of 16,190 female breast cancer patients aged between 35 and 80 years from 2003 to 2010. These breast cancer patients were then individually matched by age to control female group (1:2 ratios of cases and controls). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated via multivariable logistic regression by setting normal BMI range (18.5–22.9) as the reference group.

Results

In premenopausal women, the risk of breast cancer of triple-negative subtype increased (OR 1.60, 95% CI 1.27–2.02) in obese II (BMI ≥ 30) women and in underweight women, it was Luminal A (OR 1.24, 95% CI 1.06–1.45) and HER2 express subtype (OR 1.43, 95% CI 1.26–1.62) that showed increased risk of breast cancer. In postmenopausal women, Luminal A (OR 2.35, 95% CI 2.01–2.75), Luminal B HER2 negative (OR 1.81, 95% CI 1.46–2.25) and triple-negative subtype (OR 2.25, 95% CI 1.85–2.72) showed higher risk of breast cancer in obese II women.

Conclusion

Our findings suggest that the effect of BMI on breast cancer differs according to various subtypes and hormone receptors and to menopausal status.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRef
2.
Jung K-W, Won Y-J, Oh C-M, Kong H-J, Lee DH, Lee KH (2017) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49(2):292CrossRef
3.
Park EH, Min SY, Kim Z, Yoon CS, Jung K-W, Nam SJ, Oh SJ, Lee S, Park B-W, Lim W (2017) Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer 20(1):1–11CrossRef
4.
Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, Ishida T, Fukao A, Tsuji I, Ohuchi N (2010) Adiposity, adult weight change and breast cancer risk in postmenopausal Japanese women: the Miyagi Cohort Study. Br J Cancer 103(9):1443–1447CrossRef
5.
Sweeney C, Blair CK, Anderson KE, Lazovich D, Folsom AR (2004) Risk factors for breast cancer in elderly women. Am J Epidemiol 160(9):868–875CrossRef
6.
Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE (2009) Breast cancer risk factors defined by estrogen and progesterone receptor status the multiethnic cohort study. Am J Epidemiol 169:1251–1259CrossRef
7.
Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, Hainaut P (2013) Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev 14(8):665–678CrossRef
8.
Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 89(5):396–397CrossRef
9.
Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC (1985) Do regular ovulatory cycles increase breast cancer risk? Cancer 56(5):1206–1208CrossRef
10.
Millikan RC, Newman B, Tse C-K, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139CrossRef
11.
Li H, Sun X, Miller E, Wang Q, Tao P, Liu L, Zhao Y, Wang M, Qi Y, Li J (2017) BMI, reproductive factors, and breast cancer molecular subtypes: a case-control study and meta-analysis. J Epidemiol 27(4):143–151CrossRef
12.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dąbrowska N, Bardin-Mikolajczak A (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Prev Biomark 16(3):439–443CrossRef
13.
Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko S-S, Han W (2007) Poor outcome of hormone receptor–positive breast cancer at very young age is due to Tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368CrossRef
14.
Kim Y, Han B-G (2016) Cohort profile: the Korean genome and epidemiology study (KoGES) Consortium. Int Epidemiol 46(2):e20CrossRef
15.
Organization WH (2000) The Asia-Pacific perspective: redefining obesity and its treatment. In: Sydney: Health Communications Australia
16.
Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H-J (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747CrossRef
17.
Goldhirsch A, Winer EP, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H-J, Albain KS, André F (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223CrossRef
18.
Stekhoven DJ, Bühlmann P (2011) MissForest—non-parametric missing value imputation for mixed-type data. Bioinformatics 28(1):112–118CrossRef
19.
Millikan RC, Newman B, Tse C-K, Moorman PG, Conway K, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139CrossRef
20.
Cleary MP, Maihle NJ (1997) The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 216(1):28–43CrossRef
21.
Rose DP, Vona-Davis L (2010) Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 66(1):33–38CrossRef
22.
Van Mieghem T, Leunen K, Pochet N, De Moor B, De Smet F, Amant F, Berteloot P, Timmerman D, Bempt IV, Drijkoningen R (2007) Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Res Treat 106(1):127–133CrossRef
23.
Laidlaw I, Clarke RB, Howell A, Owen A, Potten CS, Anderson E (1995) The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136(1):164–171CrossRef
24.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578CrossRef
25.
26.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578CrossRef
27.
Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A (2006) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRef
Metadata
Title
Body mass index and risk of breast cancer molecular subtypes in Korean women: a case–control study
Authors
Seok Hun Jeong
Yoonsuk An
Choonghyun Ahn
Boyoung Park
Min Hyuk Lee
Dong-Young Noh
Sue K. Park
Publication date
01-01-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05451-1

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue

Epidemiology

Flat epithelial atypia: are we being too aggressive?

Clinical trial

The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study

Preclinical study

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer

Epidemiology

Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study

Epidemiology

The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk

Clinical trial

Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits